: [117] [118] [119] [120] [121] [122] [123] [124] [125] n INTRODUZIONE I n systemic autoimmune diseases, chronic activation of the immune system is classically linked to the development of tissue damage. Both the cellular and the humoral arms of the immune system promote an amplification loop, fueling continuing inflammation, activation of intrinsic resident cells, and final tissue injury. Whilst the close inter-relationship between aberrant autoimmune reactions and organ damage has long been recognized in prototypical settings such as lupus nephritis and ANCAassociated vasculitides (1, 2) , a wide range of evidence now suggests that immune signaling cascades also profoundly influence the pathologic remodeling of a tissue previously viewed as immunologically inert, that is to say the skeletal system (3). Bone loss is a common feature of chronic rheumatic diseases. In particular, rheumatoid arthritis (RA) represents the prototype of a chronic inflammatory disease accompanied by rapid bone loss. In addition to systemic osteoporosis, patients with RA develop periarticular osteopenia and joint erosions early in the disease process. Proinflammatory cytokines are traditionally regarded as key drivers of articular and extra-articular bone tissue destruction (4, 5) . However, recent experimental evidence indicates that RA-associated autoantibodies can independently stimulate bone remodeling by inducing the differentiation of bone resorbing osteoclasts (OCs) (6) , and B cells from RA patients can impact on bone also through non-antibody dependent mechanisms (7) . In this review, we will summarize the current knowledge linking B cell autoimmunity to bone damage in RA. We will discuss the non-autoantibody roles of B cells, as well as the direct and indirect effects of autoantibodies.
n BONE REMODELING IN RHEUMATOID ARTHRITIS: INFLAMMATORY MECHANISMS
Bone loss in RA results from an imbalance between bone resorption and bone formation (4, 5) . (Figure 1 ). The relationship between chronic synovitis and bone remodeling in RA is shown. The inflamed RA synovium produces chemokines that recruit osteoclast (OC) precursors, contains OC precursors and produces pro-inflammatory cytokines able to: promote OC differentiation and activation; inhibit osteoblast (OB) differentiation and function. Inflammatory and resident cells in RA synovium, including T lymphocytes, fibroblasts, macrophages, and others, are a source of the osteoclastogenic mediator receptor activator of nuclear factor κB ligand (RANKL) which, by binding to its cognate receptor RANK, promotes OC differentiation from macrophage lineage cells. The same cells produce large amounts of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-17, and others, which stimulate OC differentiation and activation either directly through activating OCs or indirectly by inducing RANKL production. The same pro-inflammatory cytokines, in particular TNF-α, up-regulate Dickkopf (DKK)-1 and sclerostin production. DKK-1 overexpression blocks new bone formation through antagonism of the Wingless (Wnt) signaling pathway, a critical pathway involved in OB differentiation from mesenchymal stem cells. 
Clinical evidence
Since the identification of citrullinated proteins as relevant autoantigens in RA, the association of ACPA with more joint damage progression has been replicated by several independent studies (23-25). Importantly, not only the mere presence of autoantibodies, but also the extent of the overall autoimmune response appears to impact negatively on bone. Syversen and coauthors (25) originally showed that patients with high levels of ACPA were 5 times more likely than patients with lowmoderate levels to develop radiographic progression over 10-years. In the Leiden Early Arthritis Clinic and the Norwegian EURIDISS cohort, a high number of ACPA isotypes present at baseline was associated with significantly more radiographic damage during the disease course (26). More recently, anti-carbamylated protein (anti-CarP) antibodies were shown to have a statistically significant additive value to ACPA and RF in predicting radiographic progression in ACPA-positive/RFnegative, ACPA-negative/RF-positive and ACPA-positive/RF-positive patients, with effect sizes ranging 1.05-fold to 1.17-fold rate of joint destruction per year (27). In addition to anti-CarP, other recently identified autoantibodies may potentiate the effect of ACPA. In two large prospective RA cohorts, antibodies against the human isoform 4 of peptidyl arginine deiminase (PAD) were associated with higher radiographic damage scores over time even in the presence of ACPA (28), and high levels of cross-reactive anti-PAD3/PAD4 antibodies appeared in a recent report to increase further the risk of joint destruction (29). Elegant imaging studies have provided quantitative estimation of the addictive effect of autoantibodies on the erosive burden of RA, demonstrating that RF dosedependently influences the size and number of bone erosions on an ACPA-positive background (30). Intriguingly, autoantibodies emerge as possible determinants not only of joint integrity, but also of the systemic bone mass. Both in long-standing and early RA, the presence of ACPA negatively associates with hip and spine bone review surface, and ACPA directed against mutated vimentin and purified from serum of patients with RA increase the formation and differentiation of OCs in vitro and induce bone resorption in vivo after transfer to mice. Applying these findings to human arthritis, serum markers of bone resorption and OC activity, such as C-terminal cleavage products for collagen type I, tartrate-resistant acid phosphatase 5b, and cathepsin K, were found to be specifically increased in association with ACPA-positivity in patients with early RA (47). Further studies have confirmed that polyclonal ACPA obtained from the peripheral blood or synovial fluid of patients with RA are effective in inducing osteoclastogenesis from human monocytes (48). The process of ACPA-induced OC differentiation appears dependent on a combination of intracellular protein citrullination in the OC as well as autocrine preferential production of Figure 2 -B cell contribution to bone remodeling in rheumatoid arthritis (RA).
Autoantibody-dependent mechanisms
The autoantibody-independent and autoantibody dependent contribution to bone remodeling in rheumatoid arthritis (RA) is shown. B cells infiltrating the RA synovium are a source of the osteoclastogenic mediator receptor activator of nuclear factor κB ligand (RANKL) which, by binding to its cognate receptor RANK, promotes OC differentiation and activation. Furthermore, plasma cells produce autoantibodies such as anticitrullinated protein autoantibodies (ACPA) and rheumatoid factor (RF). OC precursors express citrullinated vimentin on their surface, and ACPA directed against mutated vimentin increase the formation and differentiation of OCs. Furthermore, ACPA trigger tumor necrosis factor (TNF)-α production by macrophages through engagement of the Fcγ receptor and by direct binding to a citrullinated GRP78 cell-surface receptor. In turn, TNF-α promotes OC differentiation and activation both directly and by up-regulating RANKL production. RF can amplify OC activation by inducing TNF-α production by macrophages through engagement of the Fcγ receptor. Furthermore, OCs themselves can be activated through the Fcγ receptor, and immune complexes containing RF and ACPA can amplify TNF-α production and OC activation. (61) (62) (63) , and ACPA-positive/RF-positive concordant patients displayed higher levels of multiple circulating inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-17A, compared to double-negative and single ACPA-positive patients in a large (nearly 1500) registry across the U.S. (61) . Although full understanding of the relative contribution of ACPA and RF to RA pathology is hampered by their substantial overlap, it is noteworthy to mention some specific differences that seem to emerge from recent clinical studies. In the U.S. registry, single RF-positive patients exhibited small, albeit significant, elevations in cytokines and some clinical measures of disease activity compared to the doublenegative and single ACPA-positive subgroups (61) . Analogously, baseline data from the rituximab and golimumamb trials (2118 patients) have revealed that RFpositive patients demonstrate the highest disease activity levels regardless of ACPA status, whilst disease activity is lower in single ACPA-positive patients (64) . The opposite scenario would instead characterize the relationship with bone remodeling, where ACPA appear sufficient, and RF confers additional risk (30, 32). Based on these findings, some Authors have put forward the hypothesis that ACPA would primarily trigger bone damage through direct binding to OCs independently of disease activity, whilst the effects of RF would be predominantly mediated by the induction of local and systemic inflammation (30, 65).
n CONCLUSIONS
As pathological bone remodeling is primarily driven by inflammatory stimuli, abating disease activity remains the major goal of any treatment strategy in patients with RA. However, the recent demonstration that B-cells may directly boost OC activity via antibody-independent and -de- 
